The Journal of Bone and Joint Surgery, Vol 66, Issue 6 937-950, Copyright © 1984 by Journal of Bone and Joint Surgery, Inc
Improved acceptance of frozen bone allografts in genetically mismatched dogs by immunosuppression
VM Goldberg, GD Bos, KG Heiple, JM Zika and AE Powell
We studied the role of immunosuppressive therapy in improving the
incorporation of frozen bone allografts exchanged across strong
transplantation barriers in a canine cancellous ulnar segmental replacement
model. Dogs receiving frozen bone from donors with major histocompatibility
differences received one of three different immunosuppressive treatments.
In two groups, azathioprine and prednisolone were administered for either
twenty-eight or fifty-six days; anti-lymphocyte globulin was added for
another twenty-eight-day group in a third regimen. Frozen bone was
evaluated radiographically and histologically by criteria that quantified
the biological characteristics of the bone itself and union between the
graft and host at thirteen and twenty-six weeks after grafting. Graft
incorporation in these animals was compared with graft acceptance in a
similar group of untreated animals and in untreated animals in which bone
was exchanged across weak transplantation barriers. Complications of
immunosuppression included wound drainage, infection, weight loss, and
falling white-blood-cell counts. Seven of the original thirty-seven animals
died as a direct result of these complications. After twenty-six weeks the
grafts in the recipients receiving immunosuppression appeared
radiographically and histologically indistinguishable from those in the
untreated, genetically closely matched group and from autografts. They were
significantly better incorporated than identical allografts placed in
untreated, genetically disparate recipients. There was no difference in the
effectiveness of any of the immunosuppressive programs. Clinical Relevance:
Immunosuppression improves the biological outcome of otherwise poorly
performing frozen bone allografts in dogs. This finding suggests that
treatments that modify the immunological response of the host without major
side effects may be useful clinically in improving the success of massive
frozen bone allografts.